2021
DOI: 10.1016/s1473-3099(20)30691-5
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
38
0
3

Year Published

2021
2021
2025
2025

Publication Types

Select...
5
2

Relationship

2
5

Authors

Journals

citations
Cited by 41 publications
(42 citation statements)
references
References 24 publications
1
38
0
3
Order By: Relevance
“…Figure 1 reports the study flow for the selection of observational studies (A) and RCTs (B). The literature search identified nine RCT [9][10][11][12][13][14][15][16][17], six of which included in a Cochrane systematic review [8], the remaining three were published afterwards [12][13][14], and 13 observational studies [18][19][20][21][22][23][24][25][26][27][28][29]. Hence, overall there were 22 studies included in this review.…”
Section: Study Selection and Characteristicsmentioning
confidence: 99%
See 3 more Smart Citations
“…Figure 1 reports the study flow for the selection of observational studies (A) and RCTs (B). The literature search identified nine RCT [9][10][11][12][13][14][15][16][17], six of which included in a Cochrane systematic review [8], the remaining three were published afterwards [12][13][14], and 13 observational studies [18][19][20][21][22][23][24][25][26][27][28][29]. Hence, overall there were 22 studies included in this review.…”
Section: Study Selection and Characteristicsmentioning
confidence: 99%
“…Nine studies [12-14, 16, 17, 20-22, 30] reported the number of patients with and without symptoms. Among them, four studies were conducted in endemic areas [12,14,16,30] and five in a non-endemic setting [13,17,[20][21][22]. Overall, according to the pooled proportions, symptoms were reported in 50.4% cases (95% CI 47.6 -53.1) (Figure 2), with a significant difference in the proportion of individuals reporting symptoms between settings (Figure 2A): 58.6% (95% CI 55.0-62.2) in non-endemic versus 35.7% (95% CI 31.4-39.9) in endemic areas.…”
Section: Evaluation Of Symptomsmentioning
confidence: 99%
See 2 more Smart Citations
“…Evaluation of the risk-benefit ratio. Albendazole, ivermectin and moxidectin are well-known drugs and have little and mainly mild AEs as described to date (e.g., headache, abdominal pain) 7,10,20,[33][34][35]38 . Albendazole and ivermectin are widely used drugs in mass treatment programs against filariasis while only moxidectin is a relatively new drug, FDA-approved against onchocerciasis 39 .…”
Section: Description Of Statistical Methodsmentioning
confidence: 99%